<DOC>
	<DOCNO>NCT02781792</DOCNO>
	<brief_summary>Temozolomide ( TMZ ) chemotherapy drug approve FDA increase survival glioblastoma ( GBM ) patient beyond surgical resection radiation therapy alone . Give activity astrocytomas , TMZ commonly use grade III anaplastic astrocytoma ( AA ) well . Both grade III AA grade IV GBM high grade glioma ( HGG ) . The short half-life drug know oscillation DNA damage repair make ideal candidate chronotherapy . Chronotherapy improvement treatment outcomes minimize treatment toxicity maximize efficacy delivery medication accord time biological rhythm within patient . Chronotherapy improve outcome reduction side effect increase anti-tumor activity variety cancer , never apply treatment glioma . Based preliminary preclinical data chronotherapeutic TMZ treatment intracranial glioma xenograft success chronotherapy treatment cancer , invesitgators hypothesize time TMZ treatment alter efficacy toxicity .</brief_summary>
	<brief_title>Temozolomide Chronotherapy High Grade Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Newly diagnose recurrent high grade glioma ( WHO grade III &amp; IV ) high risk WHO grade II glioma begin treatment monthly high dose temozolomide therapy . Scheduled receive adjuvant temozolomide therapy complete concurrent temozolomide radiation therapy . At least 18 year age . Karnofsky performance status â‰¥ 60 % Ability understand willingness sign IRB approve write informed consent document . Pregnant and/or breastfeeding . Women childbearing potential must negative pregnancy test within 14 day study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>